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Abstract
We report that DNA damage induced by topoisomerase inhibitors,
including etoposide (ETO), results in a potent block to HIV-1 infec-
tion in human monocyte-derived macrophages (MDM). SAMHD1
suppresses viral reverse transcription (RT) through depletion of
cellular dNTPs but is naturally switched off by phosphorylation in
a subpopulation of MDM found in a G1-like state. We report that
SAMHD1 was activated by dephosphorylation following ETO treat-
ment, along with loss of expression of MCM2 and CDK1, and reduc-
tion in dNTP levels. Suppression of infection occurred after
completion of viral DNA synthesis, at the step of 2LTR circle and
provirus formation. The ETO-induced block was completely rescued
by depletion of SAMHD1 in MDM. Concordantly, infection by HIV-2
and SIVsm encoding the SAMHD1 antagonist Vpx was insensitive
to ETO treatment. The mechanism of DNA damage-induced block-
ade of HIV-1 infection involved activation of p53, p21, decrease in
CDK1 expression, and SAMHD1 dephosphorylation. Therefore,
topoisomerase inhibitors regulate SAMHD1 and HIV permissivity at
a post-RT step, revealing a mechanism by which the HIV-1 reser-
voir may be limited by chemotherapeutic drugs.
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Introduction
Retroviruses must reverse transcribe their RNA into DNA and inte-
grate nascent viral DNA into the host genome in order to replicate
(Skalka & Katz, 2005; Lusic & Siliciano, 2017). Increasing evidence
suggests that macrophage infection contributes to the reservoir of
infected cells that persist and prevent cure of HIV/AIDS (Alexaki
et al, 2008; Siliciano & Greene, 2011; Watters et al, 2013; Honeycutt
et al, 2016). Integration may be recognized as a form of DNA
damage, and the host DNA damage response (DDR) (Daniel et al,
1999; Jackson & Bartek, 2009) is critical for “gap repair” during the
integration process. Indeed, there is increasing evidence that key
DDR proteins are involved in retroviral infection, specifically during
integration (Daniel et al, 2003; Ariumi et al, 2005; DeHart et al,
2005; Lau et al, 2005). Furthermore, proteins able to restrict HIV
infection, including APOBEC3G and SAMHD1, have been linked to
DNA damage responses (Leonard et al, 2013; Roberts et al, 2013;
Clifford et al, 2014; Kretschmer et al, 2015).
SAMHD1 is a deoxynucleotide triphosphohydrolase (Goldstone
et al, 2011), and the mechanism of HIV restriction is thought to be
via depletion of dNTPs to levels that are insufficient for completion
of retroviral reverse transcription (RT) (Goldstone et al, 2011;
Lahouassa et al, 2012; Schmidt et al, 2015). The activity of SAMHD1
is thought to be regulated by CDK1/2-mediated phosphorylation at
amino acid T592 (Cribier et al, 2013; White et al, 2013; Antonucci
et al, 2016; Mlcochova et al, 2017). Here, we link DNA damage
in primary myeloid cells and cellular SAMHD1 activation, in the
absence of a type I interferon response. We show that DNA damage
induced by topoisomerase inhibitors activates p53 and p21, leading
to SAMHD1 T592 dephosphorylation/activation. Activated SAMHD1
mediates a block to HIV infection, which occurs after the synthesis
of full-length HIV DNA. Importantly, the etoposide (ETO)-induced
inhibition of HIV-1 can be fully abrogated by SAMHD1 depletion.
Results
DNA damage induces a post-reverse transcription block to HIV-1
in macrophages
It has been reported that HIV can induce DNA damage during inte-
gration into host DNA (Daniel et al, 2004). Moreover, certain
reports suggest that integration can be enhanced by DNA damage
induction (Ebina et al, 2012; Koyama et al, 2013). The cellular
response to DNA damage also typically involves cell cycle arrest
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and activation of DNA damage repair (DDR) (Branzei & Foiani,
2008). We reported recently that HDAC inhibitors, which are known
to induce cell cycle arrest and/or apoptosis, inhibit HIV-1 infection
in monocyte-derived macrophages (MDM) through activation of
SAMHD1 (Mlcochova et al, 2017).
Here, we investigate the impact of inducing DNA damage on
HIV-1 infection in MDM. We employed topoisomerase inhibitors,
which block the unwinding of dsDNA leading to inhibition of funda-
mental biological processes including DNA replication, transcrip-
tion, DNA repair and chromatin remodelling, by stabilizing the
DNA-single or -double breaks (Hsiang et al, 1989; Gorczyca et al,
1993). To test this, we treated MDM with 5 lM ETO for 18 h to con-
firm that ETO induced DNA damage, measured by staining for
nuclear cH2AX or 53BP1 (Fig 1A) in uninfected cells. Further, we
pretreated MDM with etoposide (ETO) or camptothecin (CTH), inhi-
bitors of topoisomerase I and II, respectively. 18 h after treatment
with titrations of inhibitors, we infected cells with VSV-G pseudo-
typed HIV-1 GFP and measured infection 48 h later by enumerating
GFP-positive cells. Both topoisomerase inhibitors blocked HIV-1
infection in a dose-dependent manner (Fig 1B). We then used the
most effective, non-cytotoxic, concentration of ETO (5 lM) (Fig 1C)
to measure its effect on MDM infection by different viruses (Fig 1D).
HIV-1 wild-type and capsid mutants N74D and P90A (known to use
alternative host cofactors for nuclear translocation) were equally
sensitive to topoisomerase inhibitors. However, HIV-2 and SIVsm,
which encode Vpx, and degrade SAMHD1, were insensitive to drug
treatment. Infection by DNA viruses, adenovirus (AdV) and herpes
simplex virus (HSV), and RNA virus Semliki Forest virus (SFV), was
also insensitive to topoisomerase inhibition.
We next investigated where in the HIV-1 life cycle ETO acts. We
treated MDM with 5 lM ETO for 18 h and infected cells with VSV-G
pseudotyped HIV-1 GFP (known to use an endocytic entry route) or
wild-type macrophage and CCR5 tropic HIV-1 isolate BaL and deter-
mined infection (Fig 1E and F). Both viruses were equally sensitive
to the ETO-mediated inhibition of viral infection, suggesting inde-
pendence of drug sensitivity from viral route of entry. MDM infected
with HIV-1 BaL were used for DNA isolation and qPCR to determine
efficiency of reverse transcription (Fig 1G), viral 2LTR circle forma-
tion (a measure of nuclear entry) (Fig 1H; De Iaco et al, 2013) and
viral integration by Alu-gag PCR (Fig 1I). Surprisingly, reverse tran-
scription was not affected by ETO treatment (Fig 1G), but we
observed a decrease in 2LTR circles (Fig 1H) and viral integration
(Fig 1I). We also confirmed that ETO did not affect RT products at
increasing MOI (determined as ffu/target cell), even though infec-
tion was significantly decreased (Fig 1J and K). Importantly, ETO
did not have any effect on RT products over a time-course (Fig 1L).
In addition, although dNTP levels are already very low in MDM, we
detected a decrease in dTTP and dCTP after ETO treatment
(Fig EV1).
DNA damage-induced HIV-1 block is SAMHD1 dependent
in macrophages
We observed that lentiviruses encoding Vpx (HIV-2 and SIVsm), a
SAMHD1 antagonist (Hrecka et al, 2011; Laguette et al, 2011),
were insensitive to ETO in MDM suggesting that SAMHD1 might
be responsible for the effect of ETO/CTH on HIV-1 infection
(Fig 1D). To test this, we treated MDM with 5 lM ETO, infected
cells with HIV-1 and assayed phosphorylation of SAMHD1 at T592
by immunoblot (Fig 2A–C). We found that SAMHD1 is phosphory-
lated in untreated MDM allowing efficient HIV infection, con-
firming previous data (Mlcochova et al, 2017). Addition of ETO
▸Figure 1. Etoposide/Camptothecin-induced DNA damage inhibits HIV-1 infection.A Monocyte-derived macrophages (MDM) were treated with 5 lM etoposide (ETO) for 18 h. Cells were stained for cH2AX and 53BP1 nuclear foci, acquired and
analysed using the automated cell-imaging system Hermes WiScan and ImageJ. On average, 104 cells were acquired and analysed (n = 3, mean  s.e.m.;
*P-value ≤ 0.05; paired t-test). Scale bars, 10 lm.
B MDM were treated with increasing concentrations of etoposide (ETO) and camptothecin (CTH) 18 h before infection. Cells were infected with VSV-G pseudotyped
HIV-1 GFP in the presence of ETO/CTH, and 104 cells in each experiment were recorded and analysed for GFP expression 48 h post-infection using an automated
cell-imaging system Hermes WiScan and ImageJ (n = 3, mean  s.e.m.).
C MDM were treated with increasing concentrations of ETO and CTH for 66 h. Cells were stained to distinguish between live and dead cells using LIVE/DEAD fixable
Dead cell stain protocol. Percentages of live/dead cells were determined using automated cell-imaging system Hermes WiScan and ImageJ. Addition of 20% ethanol
for 10 min into cells treated with ETO was used as positive control (n = 3, mean  s.e.m.).
D MDM were treated with 5 lM ETO for 18 h and infected in the presence of ETO with VSV-G pseudotyped HIV-1 GFP viruses wild-type (wt) HIV-1 capsid mutants
(N74D or P90A), HIV-2, SIV sooty mangabey (SIVsm E543), replication competent adenovirus type 5 AdV (AdV), Semliki Forest virus (SFV) and HSV-1. The percentages
of infected cells were determined using an automated cell-imaging system Hermes WiScan and ImageJ and normalized to untreated control ~100% (n = 3,
mean  s.e.m.; **P-value ≤ 0.01; ***P-value ≤ 0.001; (ns) non-significant, paired t-test). Cells from a representative donor were used for immunoblotting.
E MDM were treated with 5 lM ETO for 18 h and infected in the presence of ETO with VSV-G pseudotyped HIV-1 GFP. 104 cells were recorded and analysed for GFP
expression 48 h post-infection using an automated cell-imaging system Hermes WiScan and ImageJ (n = 4, mean  s.e.m.; ***P-value ≤ 0.001, paired t-test).
F MDM were treated with 5 lM ETO for 18 h and infected in the presence of ETO with full-length replication competent macrophage tropic HIV-1 virus BaL. Cells
were stained for intracellular p24, and the percentage of infected cells was quantified 48 h post-infection by FACS (n = 3, mean  s.e.m.; ***P-value ≤ 0.001, paired
t-test).
G–I MDM were treated with 5 lM ETO for 18 h and infected in the presence of ETO with HIV-1 BaL and DNA isolated 18 h post-infection for qPCR (n = 3,
mean  s.e.m.; *P-value ≤ 0.05; ***P-value ≤ 0.001; (ns) non-significant, paired t-test). (G) Late viral RT products. AZT: MDM treated with 20 lM AZT, a reverse-
transcriptase inhibitor, were used as control. (H) 2LTR circles. (I) Integrated copies of viral DNA, Alu-Gag qPCR.
J MDM were treated with 5 lM ETO for 18 h and infected with HIV-1 BaL (3, 6, 12 ffu/cell). Cells were stained for intracellular p24, and the percentage of infected
cells was quantified 48 h post-infection by FACS (n = 3, mean  s.e.m.; **P-value ≤ 0.01; ***P-value ≤ 0.001, paired t-test).
K MDM were treated with 5 lM ETO for 18 h, infected with HIV-1 BaL (3, 6, 12 ffu/cell) and DNA isolated 18 h post-infection for qPCR (n = 3, mean  s.e.m.; (ns)
non-significant, paired t-test).
L MDM were treated with 5 lM ETO for 18 h, infected with HIV-1 BaL and DNA isolated 4, 6 and 18 h post-infection for qPCR (n = 3, mean  s.e.m.; (ns) non-
significant, paired t-test).
Source data are available online for this figure.
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led to loss of SAMHD1 phosphorylation and reduced HIV-1 infec-
tivity. As expected, the inhibitory effect of ETO on HIV infection
was lost after siRNA-mediated SAMHD1 depletion (SAMHD1 KD)
(Fig 2A) or treatment of MDM with SIVmac virus-like particles
containing Vpx/Vpr (SIV VLP; Figs 2B and EV2), which was con-
firmed by a dose titration of HIV-1 virus on SAMHD1 KD
(Fig EV3A) and SIV VLP-treated cells (Fig EV3B) and by infecting
control and SAMHD1 KD cells at MOI achieving equal percentage
of infected cells (Fig EV3C and D). Importantly, the rescue was
independent of the SIV Vpr protein, as evidenced by wild-type
activity of SIV VLP deleted for Vpr (Figs 2C and EV2) but comple-
tely dependent on presence of Vpx. To investigate which step of
the virus life cycle was inhibited by ETO, and consequently
rescued by SAMHD1 depletion, we infected MDM with HIV-1 BaL
with and without co-infection with SIV VLP and isolated DNA
18 h post-infection to measure late RT products (Fig 2D), 2LTR
A
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Figure 1.
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circles (Fig 2E) and integration products (Fig 2F) under conditions
of FCS culture where SAMHD1 is phosphorylated in the absence of
ETO. Infection was measured in parallel samples 48 h post-viral
challenge (Fig 2G). Critically, the post-RT block seen on ETO treat-
ment was abrogated by SAMHD1 depletion. We conclude that HIV
inhibition following ETO treatment is mediated through SAMHD1
and impacts both nuclear import and viral integration, but not late
viral DNA synthesis.
Surprisingly, we noted that HIV-1 2LTR circles were increased by
nearly 20-fold by co-infection with SIV VLP (Fig 2E) in the absence
of ETO. However, this increase in 2LTR circles was not mirrored by
an increase in integrated proviral DNA (Fig 2E and F).
SIV bearing Vpx mutant Q76A rescues HIV-1 infection following
DNA damage
To further probe the mechanism of ETO on HIV-1 infection, we
treated MDM with 5 lM ETO for 18 h, co-infected cells with HIV-1
and SIV VLP (bearing Vpx WT/Vpr WT) or SIV VLP Q76A (bearing
Vpx Q76A mutant/Vpr WT) and measured infection 48 h later. The
Vpx mutant Q76A maintains the ability to interact with SAMHD1,
but in previous studies did not rescue HIV-1 infection from
SAMHD1, possibly because it cannot recruit DCAF1 to degrade
SAMHD1 (Srivastava et al, 2008; Hrecka et al, 2011; Laguette et al,
2011; Reinhard et al, 2014). We used MDM cultured in human
serum (low dNTP levels, dephosphorylated SAMHD1) and in FCS
(high dNTP levels, phosphorylated SAMHD1) (Mlcochova et al,
2017) and co-infected cells with HIV-1 and SIV VLP or SIV VLP
Q76A (Fig 3A and B). SIV VLP but not SIV VLP Q76A increased
infection in MDM (Fig 3A and B). By contrast, ETO-mediated inhibi-
tion of HIV-1 infection had been rescued by both SIV VLP and SIV
VLP Q76A (Fig 3A and B). ETO caused dephosphorylation of
SAMHD1 and blocked HIV-1 infection in MDM. However, this block
to infection was abrogated by SIV VLP Q76A, even though SAMHD1
was not degraded. As expected, dNTP levels following treatment
with SIV VLP Q76A infected cells were not increased (Fig EV4). Crit-
ically, SAMHD1 was dephosphorylated (active) in the presence of
ETO and SIV VLP Q76A (Fig 3C) suggesting inhibition of the active
form of SAMHD1 by the Vpx mutant without manipulation of acti-
vation by T592 phosphorylation or degradation.
To confirm which step of the virus life cycle was inhibited by
ETO and rescued by SIV VLP Q76A, we infected MDM with HIV-1
BaL with and without co-infection with SIV VLP Q76A and
measured infection (Fig 3C), late RT products (Fig 3D), 2LTR circles
(Fig 3E) and integration products (Fig 3F). We detected a ~3- to 5-
fold decrease in RT, integration of viral products and infection in
the presence of Vpx Q76A. This was independent of ETO treatment
(Fig 3C–F). Importantly, there was no reduction in reverse tran-
scription but substantial restriction of integrated provirus formation
after ETO treatment, which was rescued by co-infection with SIV
VLP Q76A (Fig 3A–F). Interestingly, we noted that HIV-1 2LTR
circles were not increased by co-infection with SIV VLP Q76A
(Fig 3E) in the absence of ETO. These data suggest that following
DNA damage, SAMHD1 can be antagonized without being degraded
or phosphorylated at T592.
ETO-induced DNA damage does not trigger type I IFN responses
in MDM
Recent evidence suggests that DNA damage activates the type I
interferon system to anti-microbial responses (Brzostek-Racine et al,
2011; Hartlova et al, 2015). As SAMHD1 was shown to mediate
spontaneous expression and release of IFN when mutated (Crow &
Manel, 2015) or deleted (Behrendt et al, 2013), we investigated the
possibility that DNA damage induction could activate a type I IFN
response and block HIV-1 infection in MDM.
To test this, we treated MDM with 5 lM ETO for 18 h to induce
DNA damage. As a positive control for innate immune triggering,
we treated MDM with cGAMP, the product of the activated DNA
sensor cGAS (Sun et al, 2013; Wu et al, 2013) or IFN-b for 18 h. We
then isolated RNA from the cells and tested for specific interferon-
stimulated gene (ISG) transcripts (Fig 4A). None of the ISG tran-
scripts tested was strongly elevated after ETO exposure of MDM.
Moreover, an immunofluorescence/translocation assay detected
5–20% of IRF3-positive nuclei in MDM after treatment with cGAMP
and LPS (positive controls), consistent with activation of innate
immune responses. However, there was no IRF3 translocation to the
nucleus after 2, 6 or 18 h of ETO treatment (Fig 4B and C), suggest-
ing that a type I IFN response is not strongly activated after ETO-
induced DNA damage in MDM.
▸Figure 2. SAMHD1 inhibits HIV-1 at a post-RT step following DNA damage.A MDM were transfected with control or pool of SAMHD1 (KD) siRNA and 3 days later treated with 5 lM ETO and infected in the presence of ETO with VSV-G
pseudotyped HIV-1 GFP 18 h later. Cells from a representative donor were used for immunoblotting. The percentage of infected cells was quantified by the
automated cell-imaging system Hermes WiScan and ImageJ 48 h post-infection (n = 3, mean  s.e.m.; **P-value ≤ 0.01; (ns) non-significant, paired t-test).
B MDM were treated with 5 lM ETO for 18 h and co-infected in the presence of ETO with VSV-G HIV-1 GFP and SIVmac virus-like particles containing Vpx/Vpr (SIV
VLP). Cells from a representative donor were used for immunoblotting. The percentage of infected cells was quantified by the Hermes WiScan and ImageJ 48 h
post-infection (n = 3, mean  s.e.m.; **P-value ≤ 0.01; (ns) non-significant, paired t-test).
C MDM were treated with 5 lM ETO for 18 h and co-infected in the presence of ETO with VSV-G HIV-1 GFP and SIVmac virus-like particles containing Vpx/Vpr (SIV
VLP) or deleted for Vpx (SIV VLP del Vpx) or deleted for Vpr (SIV VLP del Vpr). Cells from a representative donor were used for immunoblotting. The percentage of
infected cells was quantified by the automated cell-imaging system Hermes WiScan and ImageJ 48 h post-infection (n = 4, mean  s.e.m.; **P-value ≤ 0.01; (ns)
non-significant, paired t-test).
D–F MDM were treated with 5 lM ETO for 18 h and co-infected in the presence of ETO with HIV-1 BaL and SIVmac virus-like particles containing Vpx/Vpr (SIV VLP).
DNA was isolated 18 h post-infection for qPCR quantification of (F) late RT products; (G) 2LTR circles; (H) integrated viral DNA (n = 3, mean  s.e.m.;
*P-value ≤ 0.05; **P-value ≤ 0.01; (ns) non-significant, paired t-test). (D) Late viral RT products. AZT: MDM treated with 20 lM AZT, a reverse-transcriptase
inhibitor, were used as control. (E) 2LTR circles. (F) Integrated copies of viral DNA, Alu-Gag qPCR.
G The percentage of infected cells was quantified by Hermes WiScan and ImageJ 48 h post-infection (n = 3, mean  s.e.m.; **P-value ≤ 0.01; (ns) non-significant,
paired t-test).
Source data are available online for this figure.
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DNA damage promotes a G0 state and regulates SAMHD1
phosphorylation via p53 and p21
In the absence of general type I IFN responses after ETO treat-
ment, we hypothesized that the restriction of HIV-1 is mediated
entirely by dephosphorylation and activation of SAMHD1. Recent
evidence demonstrated that cell cycle status regulates phosphory-
lation of SAMHD1 (Cribier et al, 2013; Badia et al, 2016;
Mlcochova et al, 2017). G0 state macrophages encode active,
dephosphorylated SAMHD1, but SAMHD1 is phosphorylated and
deactivated by CDK1 in a subpopulation of macrophages in a G1-
like state (Mlcochova et al, 2017). To test whether ETO altered
cell cycle status and therefore activated SAMHD1 through the
same pathway, we treated MDM with ETO and CTH and
measured the proportion of cells in G0 or G1 by detection of
MCM2, a marker expressed throughout the cell cycle but not in
G0. In fact, the proportion of MDM expressing MCM2 and thus
being in a G1-like state was significantly reduced after ETO/CTH
treatment, indicative of cells returning to G0, a state non-
permissive to HIV-1 infection (Fig 5A). We mapped the pathway
leading to SAMHD1 dephosphorylation and HIV restriction using
immunoblotting (Fig 5B–D). ETO induced DNA damage, as
measured by an increase in cH2AX, and resulted in increased
expression of p53 and p53 phosphorylation at Ser15 (Fig 5B–D).
We also observed increased expression of p21 but not p27
protein. Moreover, absence of PARP cleavage (Fig 5B–D)
suggested lack of apoptosis, in addition supported by the lack of
cell death measured using cell viability/cell survival analysis
(Fig 1C). Loss of HIV-1 permissivity following ETO treatment also
correlated with loss of CDK1 and SAMHD1 activation by dephos-
phorylation. No increase in expression or phosphorylation of
CDK2 was detected (Fig 5B and C). The same results were
A B C
D E F
Figure 3. Vpx Q76A rescues DNA damage-induced block to HIV-1 infection.
A, B MDM were treated with 5 lM ETO for 18 h and co-infected in the presence of ETO with VSV-G HIV-1 GFP and SIVmac virus-like particles containing Vpx wild-type
(WT)/Vpr or Vpx Q76A mutant/Vpr (SIV VLP Q76A) (n = 3, mean  s.e.m.; *P-value ≤ 0.05; **P-value ≤ 0.01; (ns) non-significant, paired t-test). (A) MDM were
differentiated and cultured in human serum instead of FCS. (B) MDM were differentiated and cultured in FCS. A standard culture condition used in all experiments.
See Materials and Methods.
C–F MDM were treated with 5 lM ETO for 18 h and co-infected in the presence of ETO with HIV-1 BaL and SIV VLP Q76A. DNA was isolated 18 h post-infection for
qPCR quantification of (D) late RT products; (E) 2LTR circles; (F) integrated viral DNA (n = 3, mean  s.e.m.; *P-value ≤ 0.05; **P-value ≤ 0.01; (ns) non-significant,
paired t-test). (C) The percentage of infected cells was quantified by the automated cell-imaging system Hermes WiScan and ImageJ 48 h post-infection. Cells from
a representative donor were used for immunoblotting. (D) Late viral RT products. AZT: MDM treated with 20 lM AZT, a reverse-transcriptase inhibitor, were used as
control. (E) 2LTR circles. (F) Integrated copies of viral DNA, Alu-Gag qPCR.
Source data are available online for this figure.
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obtained with the topoisomerase I inhibitor CTH (Fig 5D). These
data suggest that a DNA damage-induced block to HIV infection
in human macrophages is mediated through cell cycle arrest acti-
vated by a p53/p21/CDK1 pathway culminating in activation of
SAMHD1 by dephosphorylation (Fig 6).
Discussion
DNA damage and repair have been implicated in regulation of HIV-1
infection, although such reports have opposed each other, likely due
to the different cellular backgrounds used (Daniel et al, 2003;
Ariumi et al, 2005; DeHart et al, 2005; Lau et al, 2005). Indeed, the
effect of DNA repair kinases including ATM, ATR, DNA-PK on
retroviral infection appears to be variable from cell line to cell line
(Yang et al, 2010). Here, we present evidence that DNA damage
induced by topoisomerase inhibitors used in cancer treatment is
associated with SAMHD1 dependent inhibition of HIV-1 infection in
primary human MDM. ETO induced activation of SAMHD1 by
dephosphorylation and activated its ability to restrict HIV-1. By
contrast, it did not restrict HIV-2 and SIVsm infections because they
encode the SAMHD1 antagonist protein Vpx. SAMHD1 was also
previously shown to inhibit HSV-1 infection by limiting viral DNA
replication, but this inhibition was reported to be independent from
SAMHD1 T592 phosphorylation status (Kim et al, 2013). Consistent
with this observation, we could not detect any effect of ETO on HSV
infection in MDM (Fig 1C).
Considerable evidence indicates that SAMHD1 is a dNTP triphos-
phohydrolase limiting levels of dNTPs and thus retroviral reverse
transcription (Goldstone et al, 2011; Lahouassa et al, 2012; Schmidt
et al, 2015; Antonucci et al, 2016) or herpes virus DNA replication
(Kim et al, 2013). Nevertheless, other reports have suggested that
there might be a second mechanism of SAMHD1 restriction inde-
pendent of dNTP regulation (White et al, 2013; Bhattacharya et al,
2016; Welbourn, 2016). Intriguingly, ETO-induced DNA damage
was associated with a decrease in dNTP levels, but not with
decrease in products of reverse transcription in MDM as might be
expected if this mode of SAMHD1-mediated restriction is the result
A
B C
Figure 4. ETO-induced DNA damage does not activate type I IFN response in MDM.
A MDM were treated with 5 lM ETO for 18 h, 3 lg/ml cGAMP and 10 ng/ml IFN-b for 18 h. RNA was isolated and qPCR performed for selected genes using TaqMan
assays. Expression levels of target genes were normalized to GAPDH (n = 3, mean  s.e.m.; *P-value ≤ 0.05; (ns) non-significant, paired t-test).
B MDM were treated with 5 lM ETO or cGAMP for 18 h or 100 ng/ml LPS for 2 h. Cells were stained and analysed for IRF3 translocation (green) into the nucleus (blue).
Scale bars: 10 lm.
C Quantification of nuclei positive for IRF3 staining (n = 3, mean  s.e.m.).
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of regulation of overall cellular dNTP levels and limitation of
reverse transcription. Given RT takes place in the cytoplasm, it
might be possible that adequate dNTP levels for RT are maintained
in the cytoplasm following ETO treatment. Instead, we observed
reduced 2LTR circle formation and integrated proviral DNA, indicat-
ing a nuclear translocation or integration defect following ETO
treatment.
It has been reported that low dNTP levels found in macro-
phages can restrict DNA gap repair during HIV-1 integration (Van
Cor-Hosmer et al, 2013) and therefore SAMHD1 could play role
in integration through its dNTP triphosphohydrolase activity
during this process. Both, formation of 2LTR circles and the gap
repair during HIV-1 integration into host genome are recognized
by cells as DNA damage and are repaired by host cell DNA
damage repair (DDR) machinery (Li et al, 2001; Skalka & Katz,
2005). DDR is highly localized into DNA damage nuclear foci
(Rothkamm et al, 2015) and it might be possible that SAMHD1
alters dNTP concentration locally at DNA damage foci where gap
repair takes place. Importantly, SAMHD1 was reported to localize
to DNA damage foci in HeLa cells (Clifford et al, 2014), and
therefore SAMHD1 could play a direct role locally at the site of
HIV integration.
The Vpx Q76A variant that is able to interact with SAMHD1, but
not DCAF1, fails to cause SAMHD1 degradation (Srivastava et al,
2008; Hrecka et al, 2011) and fails to increase dNTP levels in
dendritic cells (Reinhard et al, 2014). Concordantly, we show that
Vpx Q76A also fails to increase dNTP levels in MDM. However, we
find that this mutant Vpx Q76A is still able to rescue HIV-1 from the
effect of ETO even though SAMHD1 protein persists in its active
dephosphorylated form. Depletion of SAMHD1 (Fig 2A) illustrates
A
C D
B
Figure 5. ETO regulates SAMHD1 phosphorylation through the p53, p21 pathway.
A MDM were treated with increasing concentrations of ETO and CTH. Cells were stained for MCM2 expression, acquired and analysed using the automated cell-
imaging system Hermes WiScan and ImageJ. On average, 104 cells were acquired (n = 3, mean  s.e.m.).
B MDM were treated with 5 lM ETO, lysed and immunoblotting performed to detect cell cycle/cell cycle arrest and DNA damage-associated proteins.
C Quantification of specific proteins band intensities from immunoblot in panel (B) using a CCD camera. Intensities of protein bands were normalized to intensity of
actin protein band.
D MDM were treated with 5 lM ETO or 0.01 lM CTH for 18 h, lysed and immunoblotting performed to detect cell cycle/cell cycle arrest and DNA damage-associated
proteins.
Data information: (B–D) Each panel shows a representative example of three independent experiments.
Source data are available online for this figure.
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that the effect of ETO on HIV-1 infection in MDM is SAMHD1 depen-
dent. We suggest that Vpx Q76A interaction with SAMHD1 is suffi-
cient to disturb a local SAMHD1 restriction function acting post-RT.
Our experiments with ETO suggest that modulation of dNTP
levels can be independent from SAMHD1 restriction, supported by
our observation that Vpx Q76A cannot increase dNTP levels but still
rescues HIV-1 infection in the presence of ETO. These data are
consistent with reports of dNTP independent restriction by SAMHD1
(Bhattacharya et al, 2016; Welbourn, 2016). We speculate that
SAMHD1 may bind viral DNA directly or indirectly and therefore
mediate post-RT restriction. Further investigation is warranted to
uncover the mechanism at play.
Intriguingly, co-infection of MDM with HIV and SIV VLP, but not
with SIV VLP Q76A, led to an increase in 2LTR circles in untreated
cells, reminiscent of observations made in monocyte-derived
dendritic cells (Reinhard et al, 2014). This observation remains as
yet unexplained but suggests that Vpx can distinguish processes
leading to 2LTR circle from provirus formation in macrophages.
Recent evidence suggest that DNA damage activates the inter-
feron type I system for anti-microbial responses in murine BMDM
(Brzostek-Racine et al, 2011; Hartlova et al, 2015) or in the human
macrophage-like THP-1 cell line (Brzostek-Racine et al, 2011). Given
that SAMHD1 mutation (Crow & Manel, 2015) or deletion (Behrendt
et al, 2013) has been associated with spontaneous expression and
release of IFN in vivo we investigated type I IFN responses in human
monocyte-derived MDM after ETO-induced DNA damage. We were
unable to detect any large changes to expression of a variety of
interferon-stimulated genes. We conclude that type I IFN responses
are not significantly activated after ETO-induced DNA damage in
MDM and are therefore not responsible for the block to infection
seen.
In the absence of type I IFN related changes we were able to
demonstrate that the ETO-induced block is mediated by SAMHD1
T592 phosphorylation. Activation of p53 and the downstream p21
lead to decreased expression of CDK1, the key kinase in SAMHD1
phosphorylation (Cribier et al, 2013; Mlcochova et al, 2017). As
expected from our previous data this loss of CDK1 activity and
SAMHD1 phosphorylation was associated with transition of G1-
like MDM back into G0 state without induction of apoptosis. In
this state, SAMHD1 was dephosphorylated and able to restrict
HIV-1.
In summary, we propose a mechanism where ETO-induced
DNA damage induces SAMHD1 dephosphorylation via a canonical
p53 and p21 pathway in macrophages. As consequence of this
regulation, activated dephosphorylated SAMHD1 mediates a block
to HIV-1 nuclear import and integration in MDM. ETO and related
chemotherapeutic agents are used in HIV infected individuals for
malignancies such as lymphoma (Little et al, 2003); future work
could include exploration of the effect of subsequent DNA damage
responses on protection of myeloid target cells from HIV infection.
Such insights might assist in design of novel therapeutic interven-
tions, particularly for persistent central nervous system reservoirs
that primarily involve macrophages or related myeloid lineage
cells.
Figure 6. Proposed mechanism of action for ETO/CTH and SAMHD1 regulation.
ETO/CTH-induced DNA damage appears to promote a p53/p21-dependent pathway. This is associated with cell cycle arrest, evidenced by decrease in MCM2 expression.
Furthermore, CDK1—responsible for SAMHD1 phosphorylation—is downregulated. As a result, SAMHD1 is not phosphorylated and becomes active against HIV-1 infection.
Dephosphorylated, active SAMHD1 induced by DNA damage appears to block 2LTR and provirus formation.
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Materials and Methods
Reagents, inhibitors, antibodies and plasmids
Tissue culture media and supplements were obtained from Invitro-
gen (Paisley, UK), and tissue culture plastic was purchased from
TPP (Trasadingen, Switzerland). FCS (FBS) was purchased from
Biosera (Boussens, France) and Sigma (Sigma, St. Louis, USA).
Human serum from human male AB plasma was of USA origin and
sterile-filtered (Sigma). All chemicals, etoposide and campthotecin
were purchased from Sigma (St. Louis, MO, USA) unless indicated
otherwise. Antibodies used were anti-cdc2 (Cell Signaling Technol-
ogy, Beverly, USA); anti-CDK2 (H-298, Santa Cruz Biotechnology);
anti-pCDK2(Thr160) (Bioss Inc., MA, USA); anti-SAMHD1
(ab67820, Abcam, UK), beta-actin (ab6276, Abcam, UK); mouse
anti-MCM2 (BM-28, BD Biosciences, UK) and rabbit anti-MCM2
(SP85) from Sigma; pSAMHD1 ProSci (Poway, CA, USA); p53
(GTX100629, GeneTex, Irvine, CA, USA); p-p53 (9286P, Cell Signal-
ing Technology); H2AX (613301, BioLegend, San Diego, CA, USA);
cH2AX (613402, BioLegend); p21(sc-6246, Santa Cruz Biotechnol-
ogy); p27 (GTX100446, GeneTex); PARP (9542T, Cell Signaling
Technology); IRF3 (11904P, Cell Signaling Technology); and 53BP1
(612522, BD Biosciences, UK). pCDNA Vpx Q76A was kind gift from
J. Luban (Reinhard et al, 2014).
Cell lines and viruses
293T cells were cultured in DMEM complete (DMEM supplemented
with 100 U/ml penicillin, 0.1 mg/ml streptomycin and 10% FCS).
SIVmac virus-like particles containing Vpx were prepared as previ-
ously described (Goujon et al, 2008). VSV-G HIV-1 GFP virus was
produced by transfection of 293T with GFP-encoding genome CSGW,
packaging plasmid p8.91 and pMDG as previously described (Besnier
et al, 2002). Stocks of macrophage tropic virus BaL were prepared by
infecting a single preparation of MDM. Cell-free supernatants were
collected from the infected cultures and stored in liquid nitrogen until
further use. Virus stocks were titrated using the focus-forming assay.
HSV-1 KOS K26GFP encoding a VP26-green fluorescent protein
(GFP) fusion protein (Blondeau et al, 2013). Ad-gfp, adenovirus
with E1 and E3 deletion, insertion of CMV-driven gfp in E1 region
was produced by Native Antigen Company, Oxfordshire. SFV was
kind gift from M. Mazzon (UCL).
Focus-forming assay
NP-2 CD4/CCR5 cells were plated in 48-well plates at a density of
1.5 × 104 cells/well, 1 day before infection. Cells were infected for
4 h, washed and cultivated for 60 h in DMEM containing 10% FCS.
Cells were fixed in methanol/acetone (1:1) and incubated for 1 h
with a mixture of two anti-HIV-1 p24 mAbs (ARP365/366) diluted
in PBS/1% FCS, washed in PBS/1% FCS and incubated for 1 h with
a secondary anti-mouse b-galactosidase-coupled antibody. After
washing with PBS/1% FCS, b-galactosidase substrate solution
(0.5 mg/ml 5-bromo-4-chloro-3-indolyl-b-galactoside in PBS
containing 3 mM potassium ferricyanide and 1 mM magnesium
chloride) was added, and the cells were incubated overnight. Blue-
stained infected cell foci were counted microscopically, and virus
titres were expressed as ffu/ml.
Monocyte isolation and differentiation
PBMC were prepared from HIV seronegative donors (after informed
consent was obtained), by density-gradient centrifugation (Lympho-
prep, Axis-Shield, UK). Monocyte-derived macrophages (MDM) were
prepared by adherence with washing of non-adherent cells after 2 h,
with subsequent maintenance of adherent cells in RPMI 1640 medium
supplemented with 10% human serum and MCSF (10 ng/ml) for
3 days and then differentiated for a further 4 days in RPMI 1640
medium supplemented with 10% fetal calf sera without M-CSF.
Infection of primary cells using full-length and VSV-G
pseudotyped HIV-1 viruses
Macrophage tropic virus BaL was added to MDM and after 4-h incuba-
tion removed and cells were washed in culture medium. Cells were
fixed in 3% PFA, permeabilized by saponin and stained for intracellu-
lar p24 using anti-p24 FITC-conjugated antibody (Santa Cruz Biotech-
nology, USA). The percentage of infected cells was monitored by flow
cytometry using BD FACSCalibur (BD Biosciences, UK) and analysed
by CellQuest (BD Biosciences) and FlowJo software (Tree Star, OR,
USA). GFP containing VSV-G pseudotyped HIV-1 was added to MDM
and after 4-h incubation removed and cells were washed in culture
medium. The percentage of infected cells was determined 48 h post-
infection by flow cytometry using BD FACSCalibur (BD Biosciences,
UK) and analysed by CellQuest (BD Biosciences) and FlowJo software
(Tree Star, OR, USA) or by Hermes WiScan automated cell-imaging
system (IDEA Bio-Medical Ltd. Rehovot, Israel) and analysed using
MetaMorph and ImageJ software.
Quantitative PCR for total HIV DNA quantitation
Total HIV DNA was detected as previously described (Mlcochova
et al, 2014). Reverse transcription inhibitor AZT (20 lM) was used
as a control to ensure that the total viral DNA measured was the
product of productive infection and not a result of DNA contamina-
tion of the viral stocks.
Integrated DNA quantitation
Integrated HIV DNA was measured as described (Liszewski et al,
2009). In total, 7,500 cells were assayed per well with five replicates
and three independent experiments.
qPCR for detection of 2-LTR circles
2 × 105 MDM were infected with 100 ng of p24 of DNaseI-treated
viruses. Cells were washed and harvested for DNA isolation 24 h
post-infection. 2-LTR circles were quantified in triplicate by qPCR as
described (Apolonia et al, 2007). Primers and probe used to detect
2-LTR circles were as follows: 50-AACTAGAGATCCCTCAGACC
CTTTT-30 and 50-CTTGTCTTCGTTGGGAGTGAATT-30, and TaqMan
probe 50-FAM-CTAGAGATTTTCCACACTGAC-TAMRA-30.
SDS–PAGE and immunoblots
Cells were lysed in reducing Laemmli SDS sample buffer contain-
ing PhosSTOP (Phosphatase Inhibitor Cocktail Tablets, Roche,
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Switzerland) at 96°C for 10 min and the proteins separated on
NuPAGE Novex 4-12% Bis–Tris gels. Subsequently, the
proteins were transferred onto PVDF membranes (Millipore,
Billerica, MA, USA), the membranes were quenched, and
proteins were detected using specific antibodies. Labelled protein
bands were detected using Amersham ECL Prime Western Blot-
ting Detection Reagent (GE Healthcare, USA) and Amersham
Hyperfilm or AlphaInnotech CCD camera. Protein band intensities
were recorded and quantified using AlphaInnotech CCD camera
and AlphaView software (Protein Simple, San Jose, California,
USA).
SAMHD1 knock-down by siRNA
1 × 105 MDM differentiated in MCSF for 4 days were transfected
with 20 pmol of siRNA (L-013950-01, Dharmacon) using Lipofec-
tamine RNAiMAX Transfection Reagent (Invitrogen). Transfection
medium was replaced after 18 h with RPMI 1640 medium supple-
mented with 10% FCS and cells cultured for additional 3 days
before infection.
Quantitative PCR–TaqMan
Total RNA was purified from cell lysates collected in RLT buffer
(Qiagen) using the RNEasy Mini kit (Qiagen). cDNA was synthe-
sized using the Omniscript RT Kit (Qiagen), and quantitative (q)PCR
of selected genes was performed using the follow ing inventoried
TaqMan assays (Applied Biosystems);
CXCL10: forward 50-TGGCATTCAAGGAGTACCTC-30 and reverse
50-TTGTAGCAATGATCTCAACACG-30. MxA: forward 50-ATCCTGGG
ATTTTGGGGCTT-30 and reverse 50-CCGCTTGTCGCTGGTGTCG-30.
ISG56: forward 50-CCTCCTTGGGTTCGTCTACA-30 and reverse 50-G
GCTGATATCTGGGTGCCTA-30. ISG54: forward 50-CAGCTGAGAA
TTGCACTGCAA-30 and reverse 50-CGTAGGCTGCTCTCCAAGGA-30.
IRF1: forward 50-TCTTAGCATCTCGGCTGGACTTC-30 and reverse
50-CGATACAAAGCAGGGGAAAAGG-30. IRF7: forward 50-GATGTCG
TCATAGAGGCTGTTGG-30 and reverse 50-TGGTCC TGGTGAAGCT
GGAA-30. STING: forward 50-TGGGGTGCCTGATAAC-30 and reverse
50-TGGCAAACAAAGTCTG-30. cGAS: forward 50-GGGAGCCCTGCTG
TAACACTTCTTAT-30 and reverse 50-TTTGCATGCTTGGGTACAAG
GT-30.
Expression levels of target genes were normalized to glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) as previously described
(Tsang et al, 2009).
Measurement of deoxynucleoside triphosphate levels in cells
dTTP and dCTP levels were measured essentially as previously
described (Arnold et al, 2015). Briefly, deoxynucleoside triphos-
phates were extracted from batches of 1 × 106 untreated and ETO-
treated macrophages according to del Val et al (2013). The dNTP
levels were quantified by radiolabel incorporation assays
performed using oligonucleotide templates detailed in Sherman &
Fyfe (1989) and the procedures described in Ferraro et al (2010)
with the following modifications. Standard curves ranged from 50
to 8,000 fmole, 5 units of Taq polymerase (Invitrogen) was used,
and 2.5 lM of a-32P-dATP was employed as an incorporation
label.
Immunofluorescence
MDM were fixed in 3% PFA, quenched with 50 mM NH4Cl and
permeabilized with 0.1% Triton X-100 in PBS or 90% methanol.
After blocking in PBS/1% FCS, MDM were labelled for 1 h with
primary antibodies diluted in PBS/1% FCS, washed and labelled
again with Alexa Fluor secondary antibodies for 1 h. Cells were
washed in PBS/1% FCS and stained with DAPI in PBS for 20 min.
Labelled cells were detected using Hermes WiScan automated cell-
imaging system (IDEA Bio-Medical Ltd. Rehovot, Israel) and anal-
ysed using MetaMorph and ImageJ software.
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